A potential association between LAG-3 and tumor reactivity is also suggested by a murine study that reported co-expression of LAG-3 and 4-1BB was sufficient to identify tumor antigen-specific yet dysfunctional CD8 T cells from syngeneic tumors, and that combination treatment with anti-LAG-3 and anti-4-1BB antibodies resulted in potent inhibition of tumor growth (56). This evidence concerns the gene CD8A and neoplasm.